FLUOROQUINOLONE RESISTANCE PATTERN AMONG THE PATHOGENS CAUSING URINARY TRACT INFECTION IN A TERTIARY CARE HOSPITAL IN KANCHIPURAM DISTRICT, TAMIL NADU, INDIA
Â Objective: The aim is to study the fluoroquinolone resistance pattern among the pathogens causing urinary tract infection (UTI).
Methods: This study was done during January to July 2016 in Tagore Medical College including both hospitalized and out patients. During this 7-month study, around 2695 urine samples were analyzed for the evidence of UTI. 718 samples were culture positive. 366 samples showed fluoroquinolones resistance (50.9%). They were screened for all fluoroquinolone drugs by doing antimicrobial susceptibility testing by Kirby-Bauer disc diffusion method as per the Clinical and Laboratory Standards Institute CLSI guidelines.
Results: The resistance pattern of different isolates to norfloxacin is Klebsiella pneumoniae - 20%, Escherichia coli - 51.4%, Enterococci - 11.1%, Proteus mirabilis - 50%, and Staphylococcus saprophyticus - 37.5%; For nalidixic acid is K pneumoniae - 25%, E. coli - 6.8%, Pseudomonas aeruginosa - 71.4%, Enterococci - 11.1%, P. mirabilis - 25%, and S. saprophyticus - 25%; For ciprofloxacin is K. pneumoniae - 5%, E. coli - 5.4%, P. mirabilis - 25%, and S. saprophyticus - 25%; and For ofloxacin is K. pneumoniae - 10%, E. coli - 5.4%, Enterococci 11.1%, and S. saprophyticus 62.5%.
Conclusion: Due to increasing resistance to fluoroquinolones in many hospitals and to make the developing resistance rates under control, empirical usage of it is either abandoned or should be restricted.
2. Hooton TM. Uncomplicated urinary tract infection. N Engl J Med 2012;366:1028-37.
3. Lichtenberger P, Hooton TM. Complicated urinary tract infections. Curr Infect Dis Rep 2008;10(6):499-504.
4. Sanjay WM, Ghorpade MV, Shivali VG, Annapurna GS, Rashmi MK. A study of vancomycin resistant enterococci isolated from urinary tract infections. Int J Pharm Pharm 2015;7(5):337-9.
5. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of anti-biotic resistant Pseudomonas aeruginosa: Comparision of risks associated with with different anti-pseudomonal agents. Antimicrob Agents Chemother 1999;43(6):1379-82.
6. Kiffer CR, Camargo EC, Shimakura SE, Ribeiro PJ Jr, Bailey TC, Pignatari AC, et al. A spatial approach for the epidemiology of antibiotic use and resistance in community-based studies: The emergence of urban clusters of Escherichia coli quinolone resistance in Sao Paulo, Brasil. Int J Health Geogr 2011;10:17.
7. Lautenbach E, Fishman NO, Biker WB, Castigloni A, Metlay JP, Edelstein PH, et al. Risk factors for fluoroquinolones resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Arch Intern Med 2002;162(21):2469-77.
8. Dholakia N, Rolston KV, Ho DH, LeBlanc B, Bodey GP. Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones. Antimicrob Agents Chemother 1994;38(4):848-52.
9. Swiatlo E, Moore E, Watt J, McDaniel LS. In vitro activity of four quinolones against clinical isolates of Pseudomonas aeruginosa determined by E test. Inf J Antimicrob Agents 2000;15:73-6.
10. Hooper DC. Quinolones. In: Mandell G, Bennett J, Dolin R, editors. Mandell, Douglas, and Bennettâ€™s Principles and Practice of Infectious Diseases. 5th ed. Philadelphia, PA: Churchill Livingstone; 2000. p. 404-13.
11. Basavaraj CM, Jyothi P. Antibiotic sensitivity pattern of Citrobacter spp. Isolated from patients with urinary tract infections in tertiary care hospital in south India. Int J Pharm Pharm 2015;7(1):252-4.
12. Wenzel RP, Sahm DF, Thornsberry C, Draghi DC, Jones ME, Kailousky JA. In vitro susceptibilities of gram negative Bacteria isolated from hospitalized patients in four European countries, Canada and the U.S in 2000-2001 to expanded spectrum of cephlosporins and comparator antimicrobials: Implications for therapy. Antimicrob Agents Chemother 2003;47:3089-98.
13. Wang H, Dzink-Fox JL, Chen M, Levy SB. Genetic characterization of highly fluoroquinolone resistant clinical E. coli strains from china: Role of acrR mutations. Antimicrob Agents Chemother 2001;45:1515-21.
14. Neaman LM, Wang SA, Ohye RG, Oâ€™Connor N, Lee MV, Weinstock HS. The epidemiology of fluoroquinolone resistant Neisseria gonorhoeae in Hawaii, 2001. Clin Infect Dis 2004;13:649-54.
15. Low DE, Hooper DC, Rubinstein E. Quinolone resistance and its clinical relevance. Quinolone Antimicrobial Agents. 3rd ed. Washington DC: American Society for Microbial Press; 2003. p. 355-86.
16. Usluer G, Ozgunes I, Leblebicioglu H, Turkish Antibiotic Utilization Study Group. A multicenter point-prevalence study: Antimicrobial prescription frequencies in hospitalized patients in Turkey. Ann Clin Microbiol Antimicrob 2005;4:16.
17. Farmer JJ, Kelly MT. Enterobacteriaceae. In: Lenette EH, Balows A, Hausler WJ, Shadomy HJ, editors. Manual of Clinical Microbiology. Washington DC: American Society for Microbiology; 1991. p. 360-83.
18. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests. Approved Standard M2 A6 (M100-S7). Wagne, PA: NCCLS; 1997.
19. World Health Organization Advisory Group on Integrated Surveillance of Antimicrobial Resistance. Critically Important Antimicrobials of Human Medicine. 3rd Revision; 2012. Available from: http//www.apps.who.int/iris/bitstream/10665/77376/1/9789241504485/eng.pdf.
20. World Health Organization. Antimicrobial Resistance: Global Report on Surveillance; 2014. Available from: http://www.who.int/drugresistance/documents/surveillancereport/en.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.